


IMMUNO PHOTONICS®

Immunophotonics, Inc.

4340 Duncan Avenue
BioGenerator Labs, Suite 212
St. Louis, MO 63110
info@immunophotonics.com
www.immunophotonics.com

Immunophotonics is a US-based privately owned clinical stage (Phase 1/2) biotech company developing a first-in-class drug (IP-001) to address the major problem of tumor recurrence after first-line locoregional procedures. A large portion of patients will have tumor recurrences, often in distant locations and organs, at which point the disease becomes much more difficult to treat.


IP-001 is designed to drive a tumor-specific adaptive immune response against the micrometastases that lead to disease progression by utilizing tumor-associated antigens released by first-line locoregional therapies (>50% of all cancer patients will receive radiation or ablation with "curative intent" during their treatment journey).



CLINICAL TRIALS

Investigator-driven trials and a phase 1b trial in Switzerland have demonstrated a favorable toxicity profile and showed early clinical signals that IP-001 is including a systemic anti-tumor immune response. The company is actively recruiting patients in the US, Switzerland, France, Germany, and the UK in two Phase 1b/2a clinical trials in very advanced cancer patients (NCT05688280, NCT03993678). Collectively, clinical trial data has shown excellent safety and tolerability across all indications, and preliminary data indicates that IP-001 can increase T cell trafficking systemically and has also demonstrated anti-tumor activity, without changing the existing workflow in the clinic.

GLOBALLY RESPECTED CLINICAL INVESTIGATORS AT RENOWNED SITES



Immunophotonics is currently initiating two Phase 2 investigator-sponsored clinical trials in target patient populations (IP-001 as adjuvant therapy to standard-of-care ablation with curative intent; readouts will be recurrence-free survival). The company is also in discussions with the largest interventional oncology organization in the world to start preparations for a pivotal Phase 2/3 trial.

COLLABORATIONS

Research Collaboration with Johnson & Johnson Enterprise Innovation Inc.

Immunophotonics recently made headlines with the announcement of a groundbreaking collaboration with Johnson & Johnson Enterprise Innovation (JJEI), marking a significant milestone for the company. This strategic partnership brings together Immunophotonics' expertise in developing cutting-edge immuno-oncology treatments with Johnson & Johnson's renowned resources and global reach in healthcare innovation. The collaboration is to explore the use of radiation to destroy tumors with IP-001, Immunophotonics' immunotherapy drug. With this collaboration, Immunophotonics and Johnson & Johnson are poised to drive forward the frontier of radiation therapy for cancer by coupling radiation-induced tumor death with IP-001-induced anticancer immune activation.

Link to press release: [Immunophotonics Announces Research Collaboration to Study Combination of Its Lead Asset with Radiotherapy \(einpresswire.com\)](https://www.einpresswire.com/article/691520924/immunophotonics-announces-research-collaboration-to-study-combination-of-its-lead-asset-with-radiotherapy)

Partnership with AngioDynamics to Explore the Power of Immunotherapy

Immunophotonics recently announced a partnership that will combine use of Immunophotonics' lead asset, IP-001 and AngioDynamics' ablation devices to explore the power of ablation in combination with immunotherapy for the treatment of solid tumor cancers. This collaborative effort extends to a partnership with the Cancer Center Amsterdam at Amsterdam University Medical Center (Amsterdam UMC) in the Netherlands.

Link to press release: <https://www.einpresswire.com/article/691520924/angiodynamics-and-immunophotonics-announces-partnership-to-explore-the-power-of-immunotherapy>